Cerebral oedema is not responsible for motor or cognitive deficits in rats with hepatic encephalopathy

Liver International

Volumn 34, Issue 3, 2014, Pages 379-387

  Cauli, Omar ^a,c   Llansola, Marta ^a   Agustí, Ana ^a   Rodrigo, Regina ^a   Hernández Rabaza, Vicente ^a   Rodrigues, Tiago B ^b   López Larrubia, Pilar ^b   Cerdán, Sebastián ^b   Felipo, Vicente ^a  

^a CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Cytotoxic oedema; Inflammation; Learning; Memory; Minimal hepatic encephalopathy; Motor function

Indexed keywords

ACUTE LIVER FAILURE; ARTICLE; BRAIN EDEMA; BRAIN WATER; COGNITIVE DEFECT; GRAVIMETRY; HEPATIC ENCEPHALOPATHY; HIPPOCAMPUS; MALE; MAZE TEST; MILD COGNITIVE IMPAIRMENT; MOTOR ACTIVITY; MOTOR COORDINATION; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEUS ACCUMBENS; PORTOCAVAL SHUNT; RAT; SPATIAL MEMORY; STUDENT T TEST; WATER CONTENT; Y-MAZE TEST; ANIMAL; CEREBELLUM; COGNITION; COMPLICATION; DISEASE MODEL; MEMORY; SCINTISCANNING; WISTAR RAT;

ANIMALS; BRAIN EDEMA; CEREBELLUM; COGNITION; DISEASE MODELS, ANIMAL; HEPATIC ENCEPHALOPATHY; MAGNETIC RESONANCE IMAGING; MALE; MAZE LEARNING; MEMORY; MOTOR ACTIVITY; PORTACAVAL SHUNT, SURGICAL; RATS; RATS, WISTAR;

EID: 84893737099     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12258     Document Type: Article

References (54)

1. Weissenborn K, Ennen JC, Schomerus H, et al. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001; 34: 768-73.
2. Weissenborn K, Giewekemeyer K, Heidenreich S, et al. Attention, memory, and cognitive function in hepatic encephalopathy. Metab Brain Dis 2005; 20: 359-6.
3. Häussinger D, Cordoba J, Kircheis G, et al. Definition and assessment of low-grade hepatic encephalopathy. In: Häussinger D, Kircheis G, Schliess F, eds. Hepatic Encephalopathy and Nitrogen Metabolism. Berlin, Heidelberg, New York: Springer, 2006; 423-32.
4. Romero-Gómez M, Boza F, Garcia-Valdecasas MS, et al. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001; 96: 2718-23.
5. Amodio P, Montagnese S, Gatta A, Morgan MY. Characteristics of minimal hepatic encephalopathy. Metab Brain Dis 2004; 19: 253-67.
6. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy - definition, nomenclature, diagnosis and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.
7. Amodio P, Schiff S, Del Piccolo F, et al. Attention dysfunction in cirrhotic patients: an inquiry on the role of executive control, attention orienting and focusing. Metab Brain Dis 2005; 20: 115-27.
8. Felipo V, Ordoño JF, Urios A, et al. Patients with minimal hepatic encephalopathy show impaired mismatch negativity correlating with reduced performance in attention tests. Hepatology 2012; 55: 530-9.
9. Bajaj JS, Saeian K, Schubert CM, et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009; 50: 1175-83.
10. Ahboucha S, Jiang W, Chatauret N, et al. Indomethacin improves locomotor deficit and reduces brain concentrations of neuroinhibitory steroids in rats following portacaval anastomosis. Neurogastroenterol Motil 2008; 20: 949-57.
11. Cauli O, Rodrigo R, Llansola M, et al. Glutamatergic and gabaergic neurotransmission and neuronal circuits in hepatic encephalopathy. Metab Brain Dis 2009; 24: 69-80.
12. Felipo V. Contribution of altered signal transduction associated to glutamate receptors in brain to the neurological alterations of hepatic encephalopathy. World J Gastroenterol 2006; 12: 7737-43.
13. Monfort P, Cauli O, Montoliu C, et al. Mechanisms of cognitive alterations in hyperammonemia and hepatic encephalopathy: therapeutical implications. Neurochem Int 2009; 55: 106-12.
14. Montoliu C, Rodrigo R, Monfort P, et al. Cyclic GMP pathways in hepatic encephalopathy. Neurological and therapeutic implications. Metabolic Brain Dis 2010; 25: 39-48.
15. Agusti A, Cauli O, Rodrigo R, et al. p38 MAP kinase is a therapeutic target for hepatic encephalopathy in rats with portacaval shunts. Gut 2011; 60: 1572-9.
16. Cauli O, Rodrigo R, Piedrafita B, et al. Inflammation and hepatic encephalopathy: ibuprofen restores learning ability in rats with porto-caval shunts. Hepatology 2007; 46: 514-9.
17. Erceg S, Monfort P, Hernández-Viadel M, et al. Oral administration of sildenafil restores learning ability in rats with hyperammonemia and with portacaval shunt. Hepatology 2005; 45: 2-10.
18. Erceg S, Monfort P, Hernandez-Viadel M, et al. Restoration of learning ability in hyperammonemic rats by increasing extracellular cGMP in brain. Brain Res 2005; 1036: 115-21.
19. Rodrigo R, Cauli O, Gomez-Pinedo U, et al. Hyperammonemia induces neuroinflammation that contributes to cognitive impairment in rats with hepatic encephalopathy. Gastroenterology 2010; 139: 675-84.
20. Häussinger D. Low grade cerebral edema and the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology 2006; 43: 1187-90.
21. Häussinger D, Kircheis G, Fischer R, et al. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 2000; 32: 1035-8.
22. Schaefer PW, Grant PE, Gonzalez RG. Diffusion-weighted MR imaging of the brain. Radiology 2000; 217: 331-45.
23. McManus ML, Churchwell KB, Strange K. Regulation of cell volume in health and disease. N Engl J Med 1995; 333: 1260-6.
24. Butterworth RF, Norenberg MD, Felipo V, et al; ISHEN Commission Expt Models HE. Experimental models of hepatic encephalopathy: ISHEN guidelines. Liver Int 2009; 29: 783-8.
25. Cauli O, Rodrigo R, Piedrafita B, et al. Neuroinflammation contributes to hypokinesia in rats with hepatic encephalopathy: ibuprofen restores its motor activity. J Neurosci Res 2009; 87: 1369-74.
26. Llansola M, Cantero JL, Hita-Yañez E, et al. Progressive reduction of sleep time and quality in rats with hepatic encephalopathy due to portacaval shunts. Neuroscience 2012; 201: 199-208.
27. Lee SH, Fisher B. Portacaval shunt in the rat. Surgery 1961; 50: 668-72.
28. Boix J, Cauli O, Leslie H, Felipo V. Differential long-term effects of developmental exposure to polychlorinated biphenyls 52, 138 or 180 on motor activity and neurotransmission. Gender dependence and mechanisms involved. Neurochem Int 2011; 58: 69-77.
29. Boix J, Cauli O, Felip V. Developmental exposure to polychlorinated biphenyls 52, 138 or 180 affects differentially learning or motor coordination in adult rats. Mechanisms involved. Neuroscience 2010; 167: 994-1003.
30. Jover R, Rodrigo R, Felipo V, et al. Brain edema and inflammatory activation in bile duct ligated rats and diet-induced hyperammonemia: a model of hepatic encephalopathy in cirrhosis. Hepatology 2006; 43: 1257-66.
31. Aguilar MA, Miñarro J, Felipo V. Chronic moderate hyperammonemia impairs active and passive avoidance behavior and conditional discrimination learning in rats. Exp Neurol 2000; 161: 704-13.
32. Monfort P, Erceg S, Piedrafita B, et al. Chronic liver failure in rats impairs glutamatergic synaptic transmission and long-term potentiation in hippocampus and learning ability. Eur J Neurosci 2007; 25: 2103-11.
33. Marmarou A, Poll W, Shulman K, Bhagavan H. A simple gravimetric technique for measurement of cerebral edema. J Neurosurg 1978; 49: 530-7.
34. Cauli O, López-Larrubia B, Rodrigues TB, et al. Magnetic resonance analysis of the effects of acute ammonia intoxication on rat brain. Role of NMDA receptors. J Neurochem 2007; 103: 1334-43.
35. Lodi R, Tonon C, Stracciari A, et al. Diffusion MRI shows increased water apparent diffusion coefficient in the brains of cirrhotics. Neurology 2004; 62: 762-6.
36. 1H-MR spectroscopy, magnetization transfer, and diffusion-weighted imaging in alcoholic and nonalcoholic patients with cirrhosis with HE. AJNR Am J Neuroradiol 2006; 27: 1019-26.
37. Kale RA, Gupta RK, Saraswat VA, et al. Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C HE. Hepatology 2006; 43: 698-706.
38. Kumar R, Gupta RK, Elderkin-Thompson V, et al. Voxel-based diffusion tensor magnetic resonance imaging evaluation of low-grade HE. J Magn Reson Imaging 2008; 27: 1061-8.
39. Bitsch A, Bruhn H, Vougioukas V, et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 1999; 20: 1619-27.
40. Wattjes MP, Harzheim M, Lutterbey GG, et al. Axonal damage but no increased glial cell activity in the normal-appearing white matter of patients with clinically isolated syndromes suggestive of multiple sclerosis using high-field magnetic resonance spectroscopy. AJNR Am J Neuroradiol 2007; 28: 1517-22.
41. 1H-nuclear magnetic resonance perspective. J Neural Transm 2006; 113: 1263-78.
42. Singhal A, Nagarajan R, Hinkin CH, et al. Two-dimensional MR spectroscopy of minimal hepatic encephalopathy and neuropsychological correlates in vivo. Magn Reson Imaging 2010; 32: 35-43.
43. 1H magnetic resonance in the study of hepatic encephalopathy in humans. Metab Brain Dis 2002; 17: 415-29.
44. Kuroiwa T, Nagaoka T, Ueki M, et al. Different apparent diffusion coefficient: water content correlations of gray and white matter during early ischemia. Stroke 1998; 29: 859-65.
45. Cauli O, Llansola M, Erceg S, Felipo V. Hypolocomotion in rats with chronic liver failure is due to increased glutamate and activation of metabotropic glutamate receptors in substantia nigra. J Hepatol 2006; 45: 654-61.
46. Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004; 40: 247-54.
47. Montoliu C, Piedrafita B, Serra MA, et al. IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy. J Clin Gastroenterol 2009; 43: 272-9.
48. Cauli O, Mansouri MT, Agusti A, Felipo V. Hyperammonemia increases GABAergic tone in cerebellum but decreases it in rat cortex. Gastroenterology 2009; 136: 1359-67.
49. Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson's disease. Parkinsonism Relat Disord 2012; 18(Suppl. 1): S210-2.
50. Bone I. The increasing importance of inflammation in neurological disease. Curr Opin Neurol 2007; 20: 331-3.
51. Monji A, Kato TA, Mizoguchi Y, et al. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsychopharmacol Biol Psychiatry 2013; 42: 115-21.
52. Di Filippo M, Sarchielli P, Picconi B, Calabresi P. Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. Trends Pharmacol Sci 2008; 29: 402-12.
53. Cagnin A, Taylor-Robinson SD, Forton DM, Banati RB. In vivo imaging of cerebral "peripheral benzodiazepine binding sites" in patients with hepatic encephalopathy. Gut 2006; 55: 547-53.
54. Cagnin A, Gerhard A, Banati RB. In vivo imaging of neuroinflammation. Eur Neuropsychopharmacol 2002; 12: 581-6.